ABIVAX Société Anonyme ABVX
As ofNov 19, 2026, 3:43 PM EST
- YTD
- -40.42%
- 1 year
- -28.86%
5D -5.81 (-6.57%)
- Market cap
- 7.03B
- Revenue (ttm)
- 4.67M
- EPS (ttm)
- -6.08
- Shares out
- 87.54M
- Forward P/E
- -21.86
- YTD return
- -40.42%
- 1-year return
- -28.86%
- 50-day average
- 93.49
- 200-day average
- 112.28
- Volume
- 1.90M
- Avg volume
- 1.11M
- Open
- 83.73
- Previous close
- 83.83
- Day's range
- 80.34 – 86.93
- 52-week range
- 69.81 – 148.83
- Beta
- -0.33
- Price target
- 163.58 (+103.6%)
- Earnings date
- Dec 21, 2026
Key statistics
- Enterprise value
- 6.15B
- Price / sales
- 1572.11
- Price / book
- 16.26
- Revenue growth
- -6.80%
- Free cash flow
- -125.90M
- Total cash
- 402.38M
- Total debt
- 1.21M
- Return on equity
- -252.35%
- Short % of float
- 4.75%
Fundamental scorecard
3 of 25 checks passed on ABVX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Analyst view
- Target (low)
- 142.00
- Target (mean)
- 163.58
- Target (high)
- 181.00
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 21, 2026
Expected Dec 21, 2026. Consensus EPS estimate -0.85675.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 21, 2026 | Sep 30, 2026 | -0.9199 | — | — | — |
| Sep 21, 2026 | Jun 30, 2026 | -0.97553 | -1.71 | -0.73 | -75.29% |
| May 22, 2026 | Mar 31, 2026 | -1.07 | -0.71 | +0.36 | +33.64% |
| Mar 23, 2026 | Dec 31, 2025 | -1.70 | -1.19 | +0.51 | +30.00% |
| Dec 15, 2025 | Sep 30, 2025 | -0.78649 | -2.47 | -1.69 | -214.27% |
| Sep 8, 2025 | Jun 30, 2025 | -0.90 | -0.86 | +0.04 | +4.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Wedbush | main | Neutral | Neutral |
| Oct 20, 2026 | Guggenheim | reit | Buy | Buy |
| Sep 22, 2026 | Truist Securities | main | Buy | Buy |
| Sep 22, 2026 | Wedbush | main | Neutral | Neutral |
| Sep 22, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Goldman Sachs | init | — | Buy |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- abivax.com
News
Your note
Sign in to keep a note on ABVX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Helikon Investments Ltd | 4.82% | 4,222,896 | 354.01M | Sep 29, 2026 |
| Darwin Global Management, Ltd. | 4.59% | 4,021,583 | 337.13M | Sep 29, 2026 |
| Vestal Point Capital, LP | 4.52% | 3,960,000 | 331.97M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 4.18% | 3,663,038 | 307.07M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 2.45% | 2,147,116 | 179.99M | Sep 29, 2026 |
| Adar1 Capital Management, LLC | 2.34% | 2,050,822 | 171.92M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ALGER INSTITUTIONAL FUNDS-Alger Focus Equity Fund | 0.69% | 607,577 | 50.93M | Jul 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.65% | 566,951 | 47.53M | Sep 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.56% | 492,838 | 41.31M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.45% | 394,782 | 33.09M | Jun 29, 2026 |
| ALGER FUNDS II-Alger Spectra Fund | 0.38% | 334,177 | 28.01M | Jul 30, 2026 |
| HARBOR FUNDS-Harbor Small Cap Growth Fund | 0.34% | 296,560 | 24.86M | Jul 30, 2026 |
